| Literature DB >> 25649381 |
Eva Lenassi1,2, Ajoy Vincent3, Zheng Li1,4, Zubin Saihan1, Alison J Coffey5, Heather B Steele-Stallard6, Anthony T Moore1, Karen P Steel5, Linda M Luxon7,8, Elise Héon3, Maria Bitner-Glindzicz6, Andrew R Webster1.
Abstract
Defects in USH2A cause both isolated retinal disease and Usher syndrome (ie, retinal disease and deafness). To gain insights into isolated/nonsyndromic USH2A retinopathy, we screened USH2A in 186 probands with recessive retinal disease and no hearing complaint in childhood (discovery cohort) and in 84 probands with recessive retinal disease (replication cohort). Detailed phenotyping, including retinal imaging and audiological assessment, was performed in individuals with two likely disease-causing USH2A variants. Further genetic testing, including screening for a deep-intronic disease-causing variant and large deletions/duplications, was performed in those with one likely disease-causing change. Overall, 23 of 186 probands (discovery cohort) were found to harbour two likely disease-causing variants in USH2A. Some of these variants were predominantly associated with nonsyndromic retinal degeneration ('retinal disease-specific'); these included the common c.2276 G>T, p.(Cys759Phe) mutation and five additional variants: c.2802 T>G, p.(Cys934Trp); c.10073 G>A, p.(Cys3358Tyr); c.11156 G>A, p.(Arg3719His); c.12295-3 T>A; and c.12575 G>A, p.(Arg4192His). An allelic hierarchy was observed in the discovery cohort and confirmed in the replication cohort. In nonsyndromic USH2A disease, retinopathy was consistent with retinitis pigmentosa and the audiological phenotype was variable. USH2A retinopathy is a common cause of nonsyndromic recessive retinal degeneration and has a different mutational spectrum to that observed in Usher syndrome. The following model is proposed: the presence of at least one 'retinal disease-specific' USH2A allele in a patient with USH2A-related disease results in the preservation of normal hearing. Careful genotype-phenotype studies such as this will become increasingly important, especially now that high-throughput sequencing is widely used in the clinical setting.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25649381 PMCID: PMC4592079 DOI: 10.1038/ejhg.2014.283
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246
Clinical characteristics and genotype of the patients with USH2A-related disease without early-onset hearing loss (discovery cohort)
| Subject; family ID | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| D1; gc4627 | 34; M | 0.00 | 0.18 | NA | No | NA | c.[2276G>T(;)13010C>T], p.[(Cys759Phe)(;)(Thr4337Met)] | NA | — | European |
| D2; gc16390 | 35; M | 0.00 | −0.10 | Nyctalopia (23 y.o.) | No | Group 3 | c.[2299delG(;)12295-3T>A], p.[(Glu767Serfs *21)][?] | Ring BE | — | European |
| D3; gc15522 | 41; M | 0.18 | 0.18 | Nyctalopia (17 y.o.) | No | Group 1 A | c.[2276G>T(;)13316C>T], p.[(Cys759Phe)(;)(Thr4439Ile)] | Ring BE | — | European |
| D4; gc5134 | 42; F | 2.20 | 0.48 | Nyctalopia (20 y.o.) | No | Group 1A | c.[ | Atrophy BE | — | South Asian |
| D5; gc17134 | 42; F | 0.24 | 0.10 | Loss of peripheral vision (26 y.o.) | No | Group 1A | c.[2276G>T(;)2276G>T], p.[(Cys759Phe)(;)(Cys759Phe)] | Ring BE | CMO | European |
| D6; gc16520 | 42; F | 0.30 | 0.18 | Nyctalopia (27 y.o.) | Yes | NA | c.[2276G>T(;)12575G>A], p.[(Cys759Phe)(;)(Arg4192His)] | Ring BE | CMO | European |
| D7; gc17055 | 43; M | 0.48 | 0.60 | Nyctalopia (15 y.o.) | Yes | NA | c.[2276G>T(;) | Ring BE | — | European |
| D8; gc16986 | 47; F | 0.00 | 0.00 | Nyctalopia (36 y.o.) | No | Group 1A | c.[2299delG(;)10073G>A] p.[(Glu767Serfs*21)(;)(Cys3358Tyr)] | Ring BE | — | European |
| D8a; gc16986 | 48; F | 0.18 | 0.18 | Nyctalopia (42 y.o.) | No | Group 2 | Ring BE | — | European | |
| D8b; gc16986 | 58; F | 0.60 | 0.60 | Nyctalopia (38 y.o.) | Yes | Group 1B | Ring BE | CMO, IOL LE | European | |
| D9; gc16172 | 48; M | −0.10 | 0.00 | Nyctalopia (30 y.o.) | No | Group 1B | c.[2332G>T(;)2332G>T], p.[(Asp778Tyr)][(Asp778Tyr)] | Ring BE | — | African |
| D14a; gc5204 | 50; M | 0.48 | 0.60 | Nyctalopia (18 y.o.) | No | NA | c.[2276G>T(;)14426C>T], p.[(Cys759Phe)(;)(Thr4809Ile)] | Ring BE | CMO | European |
| D14; gc5204 | 55; F | 0.22 | 0.40 | Dark adaptation (32 y.o.) | Yes | Group 1B | Ring BE | CMO | European | |
| D10; gc16891 | 51; F | 0.72 | 0.68 | Nyctalopia (23 y.o.) | No | Group 1A | c.[5776+1G>A(;) | Small ring BE | — | European |
| D11a; gc1985 | 50; M | 0.20 | 0.22 | Nyctalopia (13 y.o.) | No | Group 2 | c.[2299delG(;)12295-3 T>A], p.[(Glu767Serfs*21)][?] | Small ring BE | CMO, IOL BE | European |
| D11; gc1985 | 52; F | 0.28 | 0.42 | Nyctalopia (17 y.o.) | No | Group 2 | Small ring BE | IOL BE | European | |
| D12; gc15971 | 52; M | 0.22 | 0.08 | Dark adaptation (42 y.o.) | No | Group 1A | c.[7595-3C>G(;) | Ring BE | CMO | European |
| D13; gc860 | 54; M | 0.18 | 0.18 | Nyctalopia (14 y.o.) | Yes | Group 1B | c.[ | Small ring BE | IOL BE | European |
| D15; gc4654 | 55; M | 0.18 | 0.18 | Nyctalopia (32 y.o.) | Yes | NA | c.[10073G>A(;)11156G>A], p.[(Cys3358Tyr)(;)(Arg3719His)] | Ring BE | — | European |
| D16; gc16801 | 55; M | 0.18 | 0.00 | Nyctalopia (30 y.o.) | No | NA | c.[ | NA | — | South Asian |
| D17; gc16524 | 56; F | 0.78 | 0.78 | Nyctalopia (35 y.o.) | No | Group 1A | c.[2276G>T(;)10073G>A], p.[(Cys759Phe)(;)(Cys3358Tyr)] | Central hyperAF BE | IOL BE | European |
| D18; gc5399 | 58; M | 0.36 | 0.20 | Nyctalopia (12 y.o.) | No | Group 1A | c.[2276G>T(;)2299delG], p.[(Cys759Phe)(;)(Glu767Serfs*21)] | Small ring BE | CMO | European |
| D19; gc5396 | 63; F | 1.30 | 0.60 | Nyctalopia (15 y.o.) | Yes | Group 1B | c.[2276G>T(;)2299delG], p.[(Cys759Phe)(;)(Glu767Serfs*21)] | Atrophy RE; Central hyperAF LE | CMO | European |
| D20; gc1802 | 66; F | 0.50 | 1.30 | Nyctalopia (28 y.o.) | No | NA | c.[14219C>A(;) | Central hyperAF BE | — | European |
| D21; gc2053 | 68; M | 2.20 | 2.20 | Nyctalopia (15 y.o.) | No | Group 1A | c.[2802T>G(;)12575G>A], p.[(Cys934Trp)(;)(Arg4192His)] | Atrophy BE | — | European |
| D22; gc4737 | 69; M | −0.10 | 0.20 | Nyctalopia (29 y.o.) | Yes | NA | c.[2276G>T(;)13010C>T], p.[(Cys759Phe)(;)(Thr4337Met)] | Small ring BE | IOL BE | European |
| D23; gc945 | 77; F | 2.20 | 0.48 | Nyctalopia (13 y.o.) | Yes | Group 3 | c.[ | Atrophy RE; Small ring LE | CMO | European |
| Median (range) | 52 (34, 77) | 0.24 (−0.10, 2.20) | 0.2 (−0.10, 2.20) | 24.5 (12, 42) | ||||||
Abbreviations: BE, both eyes; CMO, cystoid macular oedema; FAF, fundus autofluorescence imaging; hyperAF, hyperautofluorescence, IOL, intraocular lens implants; LE, left eye; NA, not applicable; RE, right eye; VA, visual acuity.
*Age at last examination.
Audiology data: Group 1 good hearing across all frequencies (1A if <40th percentile; 1B if 50–60th percentile); Group 2 marked high-frequency hearing loss compared with low-frequency percentiles; Group 3 atypical/abnormal audiometric configuration without other aetiological explanation. Notably, in subject D2, the audiogram, although abnormal, it was not consistent with Usher syndrome type II. Conversely, subject D23, who reported adult-onset hearing loss, had an audiogram consistent with Usher syndrome type II at age 75 years (see Discussion).
Variants that are novel to this study are presented in bold. Of these novel changes, only c.3724C>T is found in the ExAC (Exome Aggregation Consortium) browser (3/122810 alleles; accessed 31 December 2014).
Subjects D8, D8a and D8b; subjects D11 and D11a; and subjects D14 and D14a are siblings. Numbering of USH2A variants has been assigned in accordance with NCBI Reference Sequence NM_206933.2.
Genotype and clinical characteristics of patients with USH2A-related disease (replication cohort)
| R1 | Retina-specific | Retina-specific | Nonsyndromic retinitis pigmentosa | ||
| R2 | c.1225T>C, p.(Trp409Arg) | Retina-specific | Unknown (novel) | Nonsyndromic retinitis pigmentosa | |
| R3 | c.9912dup, p.(Glu3305Argfs*41) | Retina-specific | Unknown | Nonsyndromic retinitis pigmentosa | |
| R4 | c.2299delG, p.(Glu767Serfs*21) | Retina-specific | Usher | Nonsyndromic retinitis pigmentosa | |
| R5 | c.99_100insT, (p.Arg34Serfs*41) | Unknown | Retina-specific | Nonsyndromic retinitis pigmentosa | |
| R6 | c.5776G>A, p.(Glu1926Lys) | Usher | Retina-specific | Nonsyndromic retinitis pigmentosa | |
| R7 | c.5776G>A, p.(Glu1926Lys) | Usher | Retina-specific | Nonsyndromic retinitis pigmentosa | |
| R8 | c.1256G>T, p.(Cys419Phe) | Usher | Retina-specific | Nonsyndromic retinitis pigmentosa | |
| R9 | c.1256G>T, p.(Cys419Phe) | Usher | Retina-specific | Nonsyndromic retinitis pigmentosa | |
| R10 | c.11864G>A, p.(Trp3955*) | c.12580T>C, p.(Cys4194Arg) | Usher | Unknown (novel) | Nonsyndromic retinitis pigmentosa |
| R11 | c.8254G>A, p.(Gly2752Arg) | c.15178T>C, p.(Ser5060Pro) | Usher | Unknown (novel) | Nonsyndromic retinitis pigmentosa |
| R12 | c.4378G>A, p.(Gly1460Arg) | c.9424G>T, p.(Gly3142*) | Unknown (novel) | Usher | Nonsyndromic retinitis pigmentosa |
| R13 | c.6904_6920dup17 | c.12877G>A, p.(Gly4293Ser) | Unknown (novel) | Unknown (novel) | Nonsyndromic retinitis pigmentosa |
| R14 | c.9611A>G, p.(His3204Arg) | c.13768G>A, p.(Gly4590Ser) | Unknown (novel) | Unknown (novel) | Nonsyndromic retinitis pigmentosa |
| R15 | c.1876C>T, p.(Arg626*) | c.1876C>T, p.(Arg626*) | Usher | Usher | Usher syndrome |
| R16 | c.1256G>T, p.(Cys419Phe) | c.2299delG, p.(Glu767Serfs*21) | Usher | Usher | Usher syndrome |
| R17 | c.2299delG, p.(Glu767Serfs*21) | c.14287G>A, p.(Gly4763Arg) | Usher | Usher | Usher syndrome |
| R18 | c.2299delG, p.(Glu767Serfs*21) | c.14287G>A, p.(Gly4763Arg) | Usher | Usher | Usher syndrome |
| R19 | c.2209C>T, p.(Arg737*) | c.2299delG, p.(Glu767Serfs*21) | Usher | Usher | Usher syndrome |
| R20 | c.2299delG, p.(Glu767Serfs*21) | c.5168-2A>G | Usher | Unknown (novel) | Usher syndrome |
| R21 | c.2299delG, p.(Glu767Serfs*21) | c.5858-1G>A | Usher | Unknown (novel) | Usher syndrome |
| R22 | c.2299delG, p.(Glu767Serfs*21) | c.14180G>A, p.(Trp4727*) | Usher | Unknown (novel) | Usher syndrome |
| R23 | c.1679delC, p.(Pro560Leufs*31) | c.11549-1G>A | Unknown | Unknown (novel) | Usher syndrome |
| R24 | c.854T>C, p.(Ile285Thr) | c.10724G>A, p.(Cys3575Tyr) | Unknown (novel) | Usher | Usher syndrome |
| R25 | c.2081G>C, p.(Cys694Ser) | c.10612C>T, p.(Arg3538*) | Unknown (novel) | Unknown (novel) | Usher syndrome |
Retina-specific corresponds to likely ‘retinal disease-specific' alleles (shown in bold).
Usher corresponds to likely ‘Usher syndrome type II'-specific alleles.
Novel corresponds to alleles that are novel to this study. Of these novel changes, the following are found in the Exome Aggregation Consortium (ExAC) browser (accessed 31 December 2014): c.12580T>C (1/122018), c.15178T>C (4/122952 alleles), c.4378G>A (3/122140) and c.9611A>G (22/122680). Segregation analysis was performed in subjects R12, R20 and R22 and has confirmed that the reported variants are in trans.
Numbering of USH2A variants has been assigned in accordance with NCBI Reference Sequence NM_206933.2.
Summary of phenotypes associated with the previously reported USH2A variants that were identified in the present series
| c.2276G>T, p.(Cys759Phe) | 96 (12 hom) | 14 | 5 | 1 | — | 1 (hom) | [ |
| c.2299delG, p.(Glu767Serfs*21) | 58 | 327 (46 hom) | 6 (3 hom) | — | 1 | — | [ |
| c.2332G>T p.(Asp778Tyr) | — | 1 | — | — | — | — | [ |
| c.2802 T>G, p.(Cys934Trp) | 1 | — | — | — | — | — | [ |
| c.3902G>T, p.(Gly1301Val) | — | — | — | 1* | — | — | [ |
| c.5776+1G>A | — | 4 | — | — | 1 | — | [ |
| 7595-3C>G, p.Pro2533Asnfs*5 | — | 5 | — | — | — | — | [ |
| c.9371+1G>C | — | 1 | — | — | — | — | [ |
| c.10073 G>A, p.(Cys3358Tyr) | 5 | — | 1 | — | — | — | [ |
| c.11156 G>A, p.(Arg3719His) | 1 | — | — | — | — | — | [ |
| c.12295-3 T>A | — | — | 1 | — | — | — | [ |
| c.12575 G>A, p.(Arg4192His) | 4 (1 hom) | — | 1 | — | — | — | [ |
| c.13010C>T, p.(Thr4337Met) | — | 2 | — | — | — | — | [ |
| c.13316C>T, p.(Thr4439Ile) | — | 5 | — | — | — | — | [ |
| c.14426C>T p.(Thr4809Ile) | — | 3 | — | — | — | — | [ |
Numbering of USH2A variants has been assigned in accordance with NCBI Reference Sequence NM_206933.2. The complete list of references can be found in LOVD-USHBase.
A single heterozygous variant in MYO7A was also reported in this patient; *a homozygous (hom) variant in MYO7A was also reported in this patient.
After reviewing the clinical data, the patient was categorised as atypical due to adult onset of hearing loss (45 years old) and normal speech.
After reviewing the clinical data, the patient was categorised as atypical due to very mild, progressive hearing loss.
Figure 1Schematic of the usherin protein and localisation of the likely disease-causing variants detected in the discovery cohort of patients (n=186); mutations previously reported in individuals with Usher syndrome type II are shown below the schematic. Presumed ‘retinal disease disease-specific' alleles are shown in red.
Figure 2(a) RT-PCR analysis of the c.12295-3T>A mutation. RT-PCR was performed on RNA extracted from nasal epithelial cells of subject D13 and an unrelated control individual, using primers located in exons 58 and 64 of USH2A. In subject D13, RT-PCR produced a shorter product of 1033 bp corresponding to skipping of USH2A exon 63 (partial sequence chromatogram of this transcript is shown in the box; the dashed line indicates the splice junction between exons 62 and 64). The other allele of subject D13 harbouring a c.12093C>A, p.(Tyr4031*) mutation did not amplify. Amplification on control template produced a band of 2550 bp, corresponding to wild-type sequence. (b) Partial sequence chromatogram of genomic DNA from subject D13 showing a heterozygous c.12093C>A variant in exon 62. Sequence analysis of the corresponding RT-PCR product (1033 bp, see above) revealed a normal sequence at c.12093; this implies that the c.12295-3T>A and c.12093C>A variants reside on different alleles. NTC stands for no template control.
Figure 3Fundus autofluorescence (FAF) imaging and foveal OCT scans of three patients with USH2A retinopathy. Three patterns were observed: (i) a hyperautofluorescent ring on FAF and preserved photoreceptor inner segment ellipsoid line in the area within the hyperautofluorescent ring on OCT (subject D8a; top row); (ii) central hyperautofluorescence on FAF and absent photoreceptor inner segment ellipsoid line on OCT (subject D17; middle row), and (iii) severely decreased autofluorescence on FAF and absent outer retina layers with thinning of the retinal pigment epithelium/Bruch's membrane complex band (subject D19; bottom row). Y.o., years old.
Figure 4Variability in the severity of ocular and audiological phenotype due to mutations in USH2A in three patients of similar age. Fundus autofluorescence (FAF) imaging and foveal OCT show a better preserved retina in subject D2 (group 3 corresponding to abnormal audiological assessment) and in a patient with Usher syndrome type II compared with subject D3 (middle panel), who has normal hearing.
Figure 5Schematic showing the proposed allelic hierarchy of USH2A mutations: the presence of at least one retinal disease-specific (‘retina-specific') USH2A allele in a patient with USH2A-related disease results in normal hearing at least in childhood.